Table III.
Survival results.
| N | Median (months) | 95%CI (months) | p-Value | |
|---|---|---|---|---|
| OS, all patients | 32 | 13.1 | 9.2–17.0 | |
| OS | ||||
| Resectable with comorbidities | 6 | Not reached | ||
| Borderline resectable | 16 | 12.0 | 8.4–15.6 | |
| Unresectable | 10 | 10.4 | 3.3–16.8 | 0.201 |
| OS | ||||
| ECOG 0 | 5 | Not reached | ||
| ECOG 1 | 21 | 13.8 | 9.0–18.6 | |
| ECOG 2–3 | 6 | 10.4 | 0.5–20.3 | 0.335 |
| OS | ||||
| No radiation | 14 | 6.4 | Not calculable | |
| Radiation | 18 | 13.1 | 10.3–15.9 | 0.702 |
| PFS, all patients | 32 | 8.8 | 5.4–12.2 | |
| PFS | ||||
| Resectable with comorbidities | 6 | Not reached | ||
| Borderline resectable | 16 | 8.4 | 5.5–11.3 | |
| Unresectable | 10 | 7.4 | 2.4–12.1 | 0.111 |
| PFS | ||||
| ECOG 0 | 5 | Not reached | ||
| ECOG 1 | 21 | 8.8 | 5.7–11.9 | |
| ECOG 2–3 | 6 | 7.4 | 4.0–10.8 | 0.369 |
| PFS | ||||
| No radiation | 14 | 5.8 | Not calculable | |
| Radiation | 18 | 8.8 | 6.2–11.5 | 0.990 |
CI: Confidence interval; ECOG: Eastern Cooperative Oncology Group; OS: overall survival; PFS: progression-free survival.